Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Lixia Sheng, Yanli Lai, Sheng Nie, Yuning Pan, Di Wang, Shanhao Tang, Kaihong Xu, Yongcheng Sun, Ping Zhang, Binbin Lai, Lieguang Chen, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 59.

https://doi.org/10.1182/blood-2025-59

Published: 2025

Journal Articles

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Lixia Sheng, Wen Lei, Duo Wu, Yi Zhang, Yanli Lai, Shuyan Wang, Duobing Zou, Ping Zhang, Kaihong Xu, Shanhao Tang, Huijie Hu, Tongyu Li, Qitian Mu, Xiaofei Ye, Hui Liu, Wenbin Qian, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2025-1929

Published: 2025

Journal Articles

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2025-3533

Published: 2025

Journal Articles

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Jiefeng Tong, Songfu Jiang, Qian Luo, Shanhu Qian, Guifang Ouyang, Yanli Lai, Huifang Jiang, Yuxia Jiang, Hui Zeng, Baodong Ye, Wei Jiang, Wenbin Qian

Blood (2024) 144 (Supplement 1): 7762.

https://doi.org/10.1182/blood-2024-204522

Published: 2024

Journal Articles

Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

Lixia Sheng, Guifang Ouyang, Yanli Lai, Sheng Nie, Di Wang, Shanhao Tang, Yuning Pan, Kaihong Xu, Yongcheng Sun, Ping Zhang, Binbin Lai, Lieguang Chen

Blood (2024) 144 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2024-198355

Published: 2024

Journal Articles

The Correlation between Alterations in the Intestinal Microbiome and Early Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B-Cell Lymphoma

Lixia Sheng, Jiaping WANG, Zhouning Lin, Yanli Lai, Guifang Ouyang

Blood (2023) 142 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2023-186700

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

The Correlation between Alterations in the Intestinal Microbiome and Early Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

The Correlation between Alterations in the Intestinal Microbiome and Early Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only